Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

The study investigated the skin-related side effects of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in 79 adult advanced breast cancer patients. The most common side effects were pruritus (itching) in 49 patients, alopecia (hair loss) in 25 patients, and eczematous lesions in 24 patients. These reactions typically occurred after a median of 6.5 months and were generally mild, with only 5% of patients needing to discontinue treatment due to the severity of the skin lesions. The majority of these skin reactions were managed with topical treatments. The study found no significant association between the type of CDK4/6i and the specific type of skin reaction reported. Age and pruritus were significant predictors of the severity of the first onset skin reaction. Despite the occurrence of these skin reactions, 95% of patients continued with the therapy. The study concluded that these skin reactions are usually mild and manageable with standard supportive care.